Allakos, Inc.

Allakos, Inc.

Allakos, Inc.

Overview
Date Founded

2012

Headquarters

975 Island Drive,Suite 201,Redwood, CA 94070

Type of Company

Public

Employees (Worldwide)

62

Industries

Pharmaceuticals
Hospitals & Patient Services
Holding Companies
Biotechnology

Company Description

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.

Contact Data
Trying to get in touch with decision makers at Allakos, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

President, Chief Executive Officer & Director

Chief Operating Officer, Chief Financial Officer

Chief Business Officer

Chief Medical Officer

Vice President, Regulatory Affairs & Drug Development

Chief Legal Officer & General Counsel

Chief Commercial Officer

Vice President, Technical Operations

Professional

Board of Directors

President & Vice President at Alta Partners III, Inc.

General Partner at NEA Management Co. LLC

President, Chief Executive Officer & Director at Allakos, Inc.

Managing Director at RiverVest Venture Management LLC

Executive Chairman, President & Chief Executive Officer at Pionyr Immunotherapeutics, Inc.

Vice President & Controller at Google, Inc.

Chief Operating Officer, Chief Financial Officer at Allakos, Inc.

Paths to Allakos, Inc.
Potential Connections via
Relationship Science
You
Allakos, Inc.
Owners & Shareholders
Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Recent Transactions
Details Hidden

Allakos, Inc. issued USD Common Stock

Details Hidden

Allakos, Inc. raised money in a private placement transaction

Details Hidden

Allakos, Inc. raised money in a private placement transaction

Insider Transactions
Transaction Advisors
Escrow Agent

Advised onAllakos, Inc. issued USD Common Stock

Underwriter

Advised onAllakos, Inc. issued USD Common Stock

Underwriter

Advised onAllakos, Inc. issued USD Common Stock

Legal Advisor

Advised onAllakos, Inc. issued USD Common Stock

Legal Advisor

Advised onAllakos, Inc. issued USD Common Stock

Legal Advisor

Advised onAllakos, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Morrison & Foerster LLP

Key Stats and Financials As of 2018
Market Capitalization
$1.62B
Total Enterprise Value
$858M
Earnings Per Share
$-2.2
Revenue
$0
Net Profit
$-43.5M
EBITDA
$-45.5M
Total Debt
$0
Total Equity
$184M
TEVNet Income
-19.7x
Debt TEV
0x
Investors
Details Hidden

New Enterprise Associates (NEA) focuses on investments in the technology and healthcare sectors. The firm's investment strategy spans all stages of a company's growth, from seeding innovations in emerging markets to funding early-stage companies in high-growth markets to fueling the growth of market leaders. NEA actively invests in emerging markets, with emphasis on India and China.NEA's investments in the healthcare sector focus on companies that address unmet or underserved clinical needs and that combine improved clinical outcomes with lower costs to the market. The firm targets three areas including biopharmaceuticals, medical devices and healthcare services. The firm has a history of partnering with companies that have pioneered transformative innovations in healthcare, such as balloon angioplasty and laparoscopic surgeryWithin the technology sector, NEA focuses on investments in the electronics, consumer technology, enterprise mobility, virtualization, tech-enabled services, SaaS and cloud computing industries.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden
Suppliers
Lonza Group AG Pharmaceuticals | Basel, BS

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Johns Hopkins University Computer Software

The Johns Hopkins University opened in 1876, with the inauguration of its first president, Daniel Coit Gilman. "What are we aiming at?" Gilman asked in his installation address. "The encouragement of research ... and the advancement of individual scholars, who by their excellence will advance the sciences they pursue, and the society where they dwell." The mission laid out by Gilman remains the university's mission today, summed up in a simple but powerful restatement of Gilman's own words: "Knowledge for the world." What Gilman created was a research university, dedicated to advancing both students' knowledge and the state of human knowledge through research and scholarship. Gilman believed that teaching and research are interdependent, that success in one depends on success in the other. A modern university, he believed, must do both well. The realization of Gilman's philosophy at Johns Hopkins, and at other institutions that later attracted Johns Hopkins-trained scholars, revolutionized higher education in America, leading to the research university system as it exists today. After more than 130 years, Johns Hopkins remains a world leader in both teaching and research. Eminent professors mentor top students in the arts and music, the humanities, the social and natural sciences, engineering, international studies, education, business and the health professions. Those same faculty members, and their research colleagues at the university's Applied Physics Laboratory, have each year since 1979 won Johns Hopkins more federal research and development funding than any other university. The university has nine academic divisions and campuses throughout the Baltimore-Washington area. The Krieger School of Arts and Sciences, the Whiting School of Engineering, the School of Education and the Carey Business School are based at the Homewood campus in northern Baltimore. The schools of Medicine, Public Health, and Nursing share a campus in east Baltimore with The Johns Hopkins Hospital. The Peabody Institute, a leading professional school of music, is located on Mount Vernon Place in downtown Baltimore. The Paul H. Nitze School of Advanced International Studies is located in Washington's Dupont Circle area. The Applied Physics Laboratory is a division of the university co-equal to the nine schools, but with a non-academic, research-based mission. APL, located between Baltimore and Washington, supports national security and also pursues space science, exploration of the Solar System and other civilian research and development. Johns Hopkins also has a campus near Rockville in Montgomery County, Md., and has academic facilities in Nanjing, China, and in Bologna, Italy. It maintains a network of continuing education facilities throughout the Baltimore-Washington region, including centers in downtown Baltimore, in downtown Washington and in Columbia. When considered in partnership with its sister institution, the Johns Hopkins Hospital and Health System, the university is Maryland's largest employer and contributes more than $10 billion a year to the state's economy

Kyowa Hakko Kirin Co., Ltd. Chemicals | Tokyo, TY

Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Competitors
Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Blueprint Medicines Corp. Biotechnology - Cambridge, MA

Blueprint Medicines Corp. is a precision therapy company, which focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Allakos, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Allakos, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Allakos, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/allakos-inc-77362891
  • https://relationshipscience.com/organization/allakos-inc-77362891